Vertex Pharmaceuticals Incorporated

🇺🇸NASDAQ Global Select
Back to all articles
Vertex Pharmaceuticals Incorporated stock analysis VRTX overview
Bullish +75

Prediction: The Trump Bull Market Is About to End -- but These Stocks Will Rise Anyway

📉 The author predicts the Trump bull market will soon end due to multiple macroeconomic headwinds.

⚠️ An attack on Iran could disrupt oil trade through the Strait of Hormuz, pushing higher gasoline and product prices.

📊 Producer price index (PPI) jumped 3.4% year over year last month, higher than expected despite excluding February's conflict impact.

📉 U.S. GDP growth slipped to 1.4% in Q4 2025, contributing concerns about economic weakness and job losses.

🏛️ The Federal Reserve faces a dilemma as cutting rates could fuel inflation while raising rates could hurt job growth.

📈 The S&P 500 Shiller CAPE ratio is near its second-highest level since early 2000, suggesting the market is priced for perfection.

💼 Berkshire Hathaway is highlighted as a safe haven with massive cash reserves to buy stocks at bargain prices during a downturn.

🏭 Enbridge benefits from increased demand for U.S. oil and gas due to Middle East turmoil while offering a 5.2% dividend yield.

💊 Vertex Pharmaceuticals is favored as a healthcare defensive play, as patients must continue taking life-saving drugs regardless of market conditions.

🧬 Vertex holds a virtual monopoly in treating cystic fibrosis and has a new non-opioid pain drug with blockbuster potential.

⚕️ The company expects to file for accelerated approval for povetacicept for IgA nephropathy in the first half of 2026.

🔬 Vertex could report results from a pivotal late-stage study of inaxaplin for APOL1-mediated kidney disease by year-end.

🏆 The Motley Fool Stock Advisor team did not include Vertex in their top 10 current buy recommendations, citing past winners like Netflix and Nvidia.

Bullish Signals
  • Vertex Pharmaceuticals enjoys a virtual monopoly in treating the underlying cause of cystic fibrosis (CF), providing strong, defensive revenue growth potential.
  • The company has a new non-opioid pain drug on the market that has blockbuster potential, adding significant upside to its portfolio.
  • Vertex could have at least one major catalyst this year with accelerated approval of povetacicept for the treatment of IgA nephropathy expected in the first half of 2026.
  • The biotech company is on track to report results from a pivotal late-stage study of inaxaplin in treating APOL1-mediated kidney disease by the end of this year.
  • Vertex belongs to the healthcare sector, which is arguably the ultimate defensive sector because patients can't stop taking life-saving drugs even if the stock market goes down.
Risk Factors
  • The Trump bull market is predicted to end, raising concerns about potential equity market declines across the S&P 500 and other major indices.
  • Inflation is expected to increase rather than decline this year due to higher oil prices from geopolitical tensions in the Strait of Hormuz, which could impact nearly every product cost.
  • The Producer Price Index (PPI) jumped 3.4% year over year last month, significantly higher than economist expectations, indicating persistent inflationary pressures.
  • U.S. GDP growth for the fourth quarter of 2025 slipped to 1.4%, signaling a weakening economy that could drag on corporate earnings.
  • The U.S. economy lost 92,000 jobs in February, reflecting ongoing labor market weakness that could persist despite the federal government shutdown being a partial factor.
  • Federal Reserve policy faces a difficult dilemma between cutting interest rates to support growth (risking inflation) or raising rates to curb inflation (hurting job growth).
  • The S&P 500 Shiller CAPE ratio is near its second-highest level since early 2000, suggesting the market is priced for perfection in a fundamentally imperfect macroeconomic environment.
  • Vertex Pharmaceuticals was not included among the Motley Fool Stock Advisor's 10 best stocks to buy now, potentially indicating weaker relative investment appeal compared to other top picks.
Full Analysis
The author predicts that the so-called "Trump bull market" is nearing its end due to significant macroeconomic headwinds, primarily driven by the escalating conflict between the U.S. and Israel against Iran. This geopolitical tension threatens to disrupt oil traffic through the Strait of Hormuz, potentially causing higher energy costs and increasing inflation across various products. Supporting this concern, data indicates that the Producer Price Index (PPI) jumped 3.4% year over year in the latest month, a figure higher than economist expectations and reflecting pre-conflict prices. Concurrently, the U.S. economy is showing signs of weakening with fourth-quarter 2025 GDP growth slipping to 1.4% and the labor market shedding 92,000 jobs in February. These factors create a difficult dilemma for the Federal Reserve regarding interest rates and valuation risks, as the S&P 500 Shiller CAPE ratio is near its second-highest level since early 2000. Despite the anticipated market downturn, the author identifies three specific stocks positioned to rise even in a bearish environment: Berkshire Hathaway (BRKA/BRKB), Enbridge (ENB), and Vertex Pharmaceuticals (VRTX). Berkshire Hathaway is highlighted as a safe haven with a massive cash stockpile left by Warren Buffett for Greg Abel, providing flexibility to acquire assets at low valuations during a market decline while its diversified insurance and utility businesses offer stability. Enbridge benefits from increased demand for U.S. oil and gas driven by Middle Eastern turmoil and serves as a utility stock offering an attractive 5.2% dividend yield with a 31-year track record of increases. Vertex Pharmaceuticals is presented as a defensive healthcare play because patient need for life-saving drugs remains constant regardless of market conditions. The company holds a virtual monopoly on treating the underlying cause of cystic fibrosis and possesses a new non-opioid pain drug with blockbuster potential. Additionally, Vertex could experience major catalysts this year, including the anticipated accelerated approval filing for povetacicept for treating IgA nephropathy in the first half of 2026 and expected results from a pivotal late-stage study of inaxaplin for APOL1-mediated kidney disease by year-end. The author concludes by noting that while Vertex was not included in The Motley Fool Stock Advisor's current top 10 list—which historically generated significant returns for Netflix and Nvidia—these three companies are recommended as resilient investments amidst the predicted end of the bull market.